Company ProfilePremium

Conduit Capital Limited

Company Profile Analysis

Ticker: CND.JO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Conduit Capital Limited - Company showcase

Year Founded & Workforce

1993

8 Employees

Conduit Capital Limited logo

Conduit Capital Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Conduit Capital Limited Overview

Conduit Capital is a small South African investment holding company. After 2015 it was rebuilt as a value-investing insurance holding company on a "float plus equity portfolio" model. In practice it was dominated by one operating asset: the Constantia Insurance Group. Constantia was a niche short- and long-term insurer writing health, medical malpractice, specialty and general property-and-casualty, funeral and assistance business in South Africa and 18 other African countries. CICL generated about 94.4% of group revenue (H1 FY2022). It was placed under curatorship by the Prudential Authority in July 2022 and into provisional liquidation in September 2022. That left Conduit with a run-off life insurer, minority private stakes and a portfolio of legal claims and disputes. Its management now pursues a stated strategy of realising assets and cutting costs. The JSE removed the listing in December 2025 after more than three years of suspension. Conduit is best understood today as a sub-scale, unlisted wind-down vehicle with contingent litigation assets and liabilities. It is no longer an operating insurer.


The company's own description

In IAR22, Conduit describes itself as a listed investment holding company on the JSE Limited, incorporated and domiciled in South Africa. Its stated vision is to grow long-term intrinsic value per share faster than the market average and ahead of its peers. The company website describes a vision of building a diversified investment group. It says the group operates mainly through two internal investment strategies, Insurance and Private Investments. ShareData's summary fact sheet, which predates the liquidation, describes Conduit as an investment holding company whose subsidiaries mostly operate in Southern African insurance. That earlier aim was to build a diversified insurance investment group alongside a non-insurance, value-oriented portfolio.

Business model as it operated (2015 – July 2022)

From June 2015 under CEO Sean Riskowitz, Conduit ran on a model modelled on Berkshire Hathaway. A Value Investors Club write-up in September 2016 called it a "mini-Berkshire":

  1. Insurance float generation. Constantia wrote niche gross premium through underwriting management agencies (UMAs), brokers and agents. Much of the risk was ceded under "solvency relief" reinsurance arrangements. These arrangements cut net written premium sharply but also cut the regulatory capital Constantia needed to hold. At 31 December 2021, float was R618.2 million (Interim H1 FY2022).

  2. Value-investing capital allocation. Float and shareholder capital were invested on Graham and Buffett principles: fractional ownership, "Mr Market", margin of safety and circle of competence (IAR22, section III). The listed equity portfolio was valued at R125.2 million at 31 December 2021.

  3. Private investments. These included 51% of Century 21 South Africa, Africa Special Opportunity Capital (ASOC) Fund I, insurtech stakes held through Conduit Ventures, and a 30% stake in Oraclemed Health Investments (acquired for R42.0 million in H1 FY2022).

Revenue model

Revenue typeDescriptionStatus
Insurance premium (short-term)Gross premium on health, medical malpractice, P&C specialty, P&C general, guarantee, liability and assistance business written by CICLCeased July 2022 (curatorship, then liquidation)
Insurance premium (long-term)Life, funeral and group risk through Constantia Life Limited (CLL) and Constantia Life & Health Assurance Company (CLAH)CLL in run-off; CLAH sale to Affinity Financial Services (R20 million) announced December 2022, completion not confirmed in sources reviewed
Investment incomeDividends, interest and fair-value movements on listed and unlisted holdingsOngoing on a reduced asset base
Franchise / brokerage incomeConsolidated through the 51% stake in Century 21 South Africa (master franchise)Status after 2022 not publicly disclosed
Commissions / administrationEarned through Constantia Risk and Insurance Holdings (CRIH) group entitiesLargely ceased

The model was transactional insurance underwriting. There was no subscription or licensing revenue. In the value chain, CICL was a risk carrier: the licensed insurer behind third-party UMAs and binder holders. The group also held minority stakes in some of those distribution and claims businesses through Conduit Ventures.

Customer types and end markets

Constantia insured individuals (gap cover and primary health products, funeral and life), professionals (medical practitioners through the EthiQal medical malpractice book), and institutions and corporates (guarantees, liability, specialty P&C, motor and property). Business was written in South Africa and, at the time of the curatorship, in 19 African countries in total including South Africa. The Star newspaper (2 August 2022) and the H1 FY2022 interim report both give this footprint.

Independent characterisation

As an analyst, I would describe Conduit before 2022 as a leveraged bet on an under-capitalised niche insurer, paired with a concentrated small-cap equity portfolio. The pairing hurt the group. Constantia's underwriting turnaround (FY2022 combined ratio below 100% and the first net underwriting profit since 2016, per the 13 June 2024 trading statement) kept being offset by mark-to-market losses in the listed portfolio. The insurer's solvency also depended on external recapitalisation that never arrived: the Trustco/LSH deal (2019–2020) and the Mmuso Consortium deal (2021–2022) both failed. After July 2022, Conduit stopped being an operating insurance group. What remains is a residual holding company. Its value depends on (a) recovering an arbitration award of R50 million plus interest against Trustco Property Holdings, (b) disposing of or transferring the run-off life insurer CLL, and (c) the outcome of a R37.4 million claim from the CICL liquidators.

Strategy

Stated strategy (IAR22 and quarterly reports, 2024–2025)

Management's strategy is defensive and focused on recovery. It has five stated themes:

Realise assets and reduce operating expenses: This is the "short-term strategy", repeated in every quarterly progress report from 2024 to 2025.

Treat the remaining insurance businesses as non-core: After the CICL liquidation, the group no longer has the scale to carry their regulatory costs. They are to be sold or restructured.

Cut operating costs by about 80%: once the planned transactions are complete. IAR22 presents this as the group's only quantified target.

Resolve disputes with the CICL liquidators: and pursue the recovery of assets owed to the group, especially the Trustco arbitration award.

Minimise expenditure: to maximise what is realised from the assets.

IAR22 explicitly states that a favourable short- to medium-term outcome is not guaranteed and that the outlook is uncertain.

Initiatives in the last 24 months (October 2024 – October 2026)

InitiativeDateStatus
Disposal of CRIH and CLL to TMM for R55 millionTerms May 2023; FST win 20 Nov 2024Lapsed 20 May 2025 after the Prudential Authority confirmed its refusal and TMM chose not to challenge
Section 50 transfer of CLL's liabilities and matching assets to a licensed insurerRaised 30 Sep 2025Under consideration; the company says it lacks surplus capital to support new business at CLL
Enforcement of the AFSA award against Trustco Properties (R50m plus interest from 10 Dec 2020)Ongoing since June 2024Enforcement steps continuing; no recovery announced
Defence of the R37.4m claim by the CICL liquidatorsFrom 3 Sep 2025Being defended; the board considers it immaterial
Publication of H1 FY2023 and FY2023 results2024–2025Halted 30 Sep 2025 pending the litigation
Board renewal after the resignationsFrom 19 Sep 2025Replacement process started; no appointments disclosed
ESG or sustainability commitmentsIAR22General SDG alignment only (SDGs 3, 5, 7, 8, 9, 10, 12, 13, 16, 17); no targets

No medium-term financial guidance has been issued.

Products & Services

All Constantia short-term products listed below stopped being written in July 2022, when the Prudential Authority barred new business. The catalogue is historical unless marked otherwise.

Pricing models were not publicly disclosed for any product. Constantia used solvency relief reinsurance extensively. This is a structural feature of the product economics rather than a product. Under these arrangements Constantia ceded "marginally profitable" gross premium in exchange for lower capital requirements. In FY2019, for example, net written premium was R387.9 million as reported, against R1,948.9 million before solvency reinsurance (FY2019 results).

Product Portfolio

SegmentProduct / offeringDescriptionTarget customerStatus

Health

Medical gap cover and primary health products

Short-term health covers that sit alongside medical scheme membership. Health was the largest line at 54% of H1 FY2022 gross premium

Individuals, through UMAs and brokers

Ceased (CICL liquidation)

Health

Medical evacuation (through Oraclemed)

Medical evacuation cover across Africa, underwritten by CICL through the Oraclemed underwriting manager

Corporates and travellers in Africa

Oraclemed moved to a replacement insurer

Medical Malpractice

EthiQal

Professional indemnity for medical practitioners. Gross premium grew 12.9% in H1 FY2022

Doctors and specialists

Ceased under CICL

P&C Specialty

Guarantee and indemnity

Guarantee products (gross premium R33.5m in FY2020)

Corporates and contractors

Ceased

P&C Specialty

Liability

Liability insurance (gross premium R205.0m in FY2020)

Businesses and professionals

Ceased

P&C Specialty

Other specialty

Grew 20.6% in H1 FY2022 with a gross loss ratio of 46.0%

Niche commercial

Ceased

P&C General

Motor and property

Personal and commercial motor and property. Being remediated in 2020–2022 (combined ratio 140.5% in H1 FY2022)

Individuals and SMEs

Ceased

Assistance

Assistance products

Gross premium R130.4m in FY2020

Policyholders through binder partners

Ceased

Life

Funeral cover

Funeral insurance. Constantia exited the funeral parlour market in December 2020

Individuals

CLL in run-off

Life

Group risk / life cover

Group risk line (gross premium R50.9m in FY2019)

Employer groups

Run-off

Private investments

Century 21 South Africa

Master franchise for a global real estate brokerage brand; 49 franchises at 31 Dec 2021; annualised return on capital 62.6% (H1 FY2022)

Real estate franchisees

Status not disclosed after 2022

Conduit Ventures

Fixico SA

Digital platform for insurers, fleet owners and car owners to manage car damage claims

Insurers and fleets

Minority stake; status not disclosed

Conduit Ventures

Rikatec

Insurtech in information management, digital solutions, big data and analytics

Insurers

Minority stake; status not disclosed

Conduit Ventures

Leymic Holdings

Insurance-related holding (named in H1 FY2022)

——

“—” = not publicly disclosed.

Financial Narrative

Disclosure limitations

The five most recent fiscal years with published group results are FY2018 to FY2022. FY2023 to FY2025 have not been published. The FY2022 group statements were disclaimed by Nexia SAB&T, because the CICL liquidators did not prepare audited CICL accounts. The company-level FY2022 statements were neither qualified nor disclaimed (IAR22, shareholders' letter). Insurance accounting does not use gross profit, EBITDA, capex intensity or a cash conversion cycle in any meaningful way, and Conduit did not report them. They are therefore blank.

Income statement and per-share data

Sources: - FY2018 and FY2019 premium and underwriting figures: FY2019 results, Table on Constantia's performance.

  • FY2019 and FY2020 GWP and per-share figures: FY2020 provisional results SENS (2 Nov 2020) and FY2020 results PDF.

  • FY2020 operating loss: FY2020 results table, last two columns. The column layout of the extracted table could not be fully verified.

  • FY2021 and FY2022 total income, attributable income, EPS, HEPS, DPS and market capitalisation: ShareData company page, "12 months ended Jun 2022 (published 30 Aug 24)".

  • The FY2022 ranges in the 13 June 2024 trading statement (LPS 44.19c–48.41c; HLPS 29.64c–33.76c) are consistent with the final figures.

  • The FY2021 GWP is not available in the sources reviewed.

Interim comparison (most granular recent disclosure)

Source: Interim results H1 FY2022 (six months to 31 Dec 2021 vs 31 Dec 2020).

Balance sheet

Source: Interim results H1 FY2022: The balance sheet as at 30 June 2022 (FY2022) is in IAR22 from page 40. Those pages could not be extracted in this research pass, so total assets, debt, net debt, goodwill and working capital at FY2022 are not reported here. They should be taken directly from IAR22 if needed.

The negative consolidated equity at 31 December 2021 is the single most important balance sheet fact. It shows that CICL's regulatory capital shortfall had already spread to the consolidated group before the regulator intervened. At the same date CICL's provisional SCR cover ratio was −0.09 and its MCR cover ratio −0.89. CLL's SCR cover was 2.28 (Interim H1 FY2022).

Net asset value per share (historical)

Sources: SENS trading statement 12 Sep 2017 (FY2016 restated NAV); FY2017 audited results. At 31 December 2017 NAV was guided at 186.1c–190.9c (SENS 20 Feb 2018). No NAV per share is published for any later period; equity attributable to the parent was negative by 31 December 2021.

Cash flow

Source: Interim results H1 FY2022. Conduit did not pay dividends or buy back shares in FY2021 or FY2022 (ShareData shows nil DPS). Capital expenditure is not a meaningful metric for this business.

Ratios

Calculated. Revenue CAGR: Constantia GWP grew at a compound 17.2% per year from FY2018 to FY2020 (R1,536.9m to R2,110.0m). GWP grew 43.6% from FY2017 (R1.07bn) to FY2018.

ROE, ROA, ROIC and debt/equity are not meaningful: equity was negative in December 2021. Interest coverage, net debt/EBITDA, the current ratio, asset turnover and the cash conversion cycle were not disclosed and cannot be calculated from the sources retrieved.

Commentary

Premium growth without capital. Constantia doubled gross written premium from 2017. Gross premium reached R2.1 billion in FY2020. However, the growth was financed largely by solvency relief reinsurance, not by equity. Underwriting losses widened from −R128.6 million (FY2018) to −R259.4 million (FY2019). By FY2019, Constantia's loss after tax was R582 million on net assets of R699 million (Trustco SENS, 11 Feb 2020).

Turnaround (FY2020–FY2022). After management was replaced in February 2020, loss-making books were cancelled. Gross premium fell 14.4% in H1 FY2021 and then grew again. By FY2022, gross written premium was up 8.3% and the combined ratio was below 100%. The trading statement describes this as the first net underwriting profit since 2016. Loss per share narrowed from 92.8c (FY2019) to 21.1c (FY2021).

FY2022 inflection. The FY2022 attributable loss more than doubled to R318.5 million. The cause was R225.0 million (32.7c per share) of impairments and write-downs linked to the CICL liquidation, recognised in FY2022 as events after the reporting date. Mark-to-market losses on the listed portfolio also contributed (IAR22). Investment losses were the main recurring drag throughout: −R33.3 million in H1 FY2021 and −R46.4 million in H1 FY2022, against roughly break-even insurance operations.

Post-FY2022. From August 2022 the group consolidates only one month of CICL. Management guided that completing the planned disposals would cut operating costs by about 80% (IAR22). That outcome is now in doubt, because the TMM disposal lapsed in May 2025.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityOwnershipRoleStatus

Conduit Capital Limited

Holding company

Investment holding

Active; unlisted since 19 Dec 2025

Constantia Risk and Insurance Holdings (Pty) Ltd (CRIH)

100%

Intermediate insurance holding company

Active; holder of the R50m Trustco award

Constantia Insurance Company Limited (CICL)

100% (control lost July 2022)

Short-term insurer; about 94.4% of group revenue in H1 FY2022

In liquidation since 14 Sep 2022

Constantia Life Limited (CLL)

100%

Long-term insurer

Run-off; no new business since 2019 (Moonstone). Section 50 transfer under consideration

Constantia Life & Health Assurance Company Ltd (CLAH)

100%

Long-term insurer

Sale to Affinity Financial Services for R20m announced Dec 2022; completion not confirmed

Copper Sunset Trading 186 (Pty) Ltd

100%

Holding vehicle and party to the TMM sale

Active

Conduit Ventures (Pty) Ltd

100%

Holds insurtech and insurance-related minority stakes (Fixico SA, Rikatec, Leymic Holdings)

Winding-up application dismissed Aug 2024

Century 21 South Africa

51%

Real estate master franchise

Status after 2022 not publicly disclosed

ASOC Fund I LP

Minority LP interest

Special situations fund launched 2017

Status not disclosed

Oraclemed Health Investments

30% (via Constantia)

Underwriting manager for medical evacuation in Africa

Found a replacement carrier after the CICL liquidation (Moonstone)

Segment Revenue

Segment (gross premium, ZAR Mn)H1 FY2021H1 FY2022

Health

513.6557.5

Medical Malpractice (EthiQal)

104.9118.4

P&C Specialty

180.0217.1

P&C General

129.1108.3

Funeral and Assistance

27.223.3

Total gross premium

954.81,024.6

Revenue by Segment (%)

Segment (% of gross premium)H1 FY2021H1 FY2022

Health

53.854.4

Medical Malpractice

11.011.6

P&C Specialty

18.921.2

P&C General

13.510.6

Funeral and Assistance

2.92.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment combined ratio (%)

Segment combined ratio (%)H1 FY2021H1 FY2022

Health

92.592.1

Medical Malpractice

82.385.6

P&C Specialty

101.299.9

P&C General

115.8140.5

Funeral and Assistance

133.1119.2

Group before solvency reinsurance cost

98.098.7

Group after solvency reinsurance cost

99.8100.4

Revenue by Segment

Sub-segment GPI (ZAR Mn)FY2019FY2020FY2021

P&C Specialty

202293337

P&C General

483277221

EthiQal (Medical Malpractice)

156204215

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Business Lines

Line (ZAR Mn)FY2019FY2020

Assistance — gross premium

76.2130.4

Assistance — underwriting result

-30.5-18.6

Guarantee — gross premium

30.033.5

Guarantee — underwriting result

4.010.9

Liability — gross premium

181.6205.0

Liability — underwriting result

27.530.8

Key Financials and Per-Share Data

MetricFY2018FY2019FY2020FY2021FY2022

Constantia gross written premium (ZAR Mn)

1,536.92,050.72,110.0——

Net written premium as reported (ZAR Mn)

392.5387.9———

Net written premium before solvency reinsurance (ZAR Mn)

1,273.31,948.9———

Constantia net underwriting result incl. solvency reinsurance (ZAR Mn)

-128.6-259.4———

Group total income (ZAR Mn)

———1,122.61,138.0

Operating loss as reported (ZAR Mn)

—-671.8-608.0——

Attributable income (ZAR Mn)

———-145.8-318.5

Basic EPS (ZAR cents)

—-92.8-80.7-21.1-46.3

Headline EPS (ZAR cents)

—-88.7-77.6-20.6-31.7

Dividend per share (ZAR cents)

———00

Market capitalisation at year end (ZAR Mn)

———413.0289.1

Balance Sheet and Per-Share Data

Metric (ZAR Mn unless stated)H1 FY2021H1 FY2022

Gross premium

954.81,024.6

Operating profit or loss from insurance operations

1.8-4.4

Net non-insurance loss

-15.8-13.3

Operating loss

-14.0-17.8

Investment loss

-33.3-46.4

Loss before taxation

-54.4-74.8

Loss for the period

-50.1-76.3

Loss attributable to equity holders

-51.8-76.6

Headline loss

-58.2-76.2

Basic loss per share (ZAR cents)

-7.5-11.1

Headline loss per share (ZAR cents)

-8.4-11.1

Balance Sheet

Metric (ZAR Mn)30 Jun 202131 Dec 202031 Dec 2021

Total assets

1,408.81,568.81,463.2

Cash and cash equivalents

—93.7179.3

Listed investments at fair value

——125.2

Unlisted investments at fair value

——24.2

Total equity

——-59.3

Equity attributable to owners of parent

——-58.5

Insurance float

——618.2

Per-Share Data

MetricFY2016FY2017

NAV per share (ZAR cents)

169.5176.1

Key Financials

Metric (ZAR Mn)H1 FY2022

Operating cash inflow

34.3

Net float generated in period

55.1

Margin Analysis (%)

RatioFY2021FY2022

Net margin on total income (%)

-13.0-28.0

Total income growth (%)

—1.4

Attributable loss growth (%)

—-118.5

Region Overview

RegionDescriptionSource

South Africa

Primary market for all lines, and the domicile of all insurance licences

IAR22; Interim H1 FY2022

Rest of Africa

Business written in 18 other African countries, including medical evacuation through Oraclemed

Interim H1 FY2022; The Star, 2 Aug 2022

Namibia

No operating revenue. This was the location of the Herboths land asset in the failed Trustco transaction and of the counterparty to the arbitration award

Trustco SENS 11 Feb 2020

United States

No revenue. Several former directors (Riskowitz, Maizey, Solberg) were linked to US-based investment managers

IAR22

Region revenue (ZAR Mn)

FY2020

FY2021

Valuation Snapshot

MetricValueSource

Listing status

Removed from the JSE on 19 Dec 2025

JSE SENS 11 Dec 2025

Suspension

From 21 Sep 2022

JSE SENS 11 Dec 2025

Last traded price before suspension

About 4c (closed at 4c after a 33% fall in early September 2022)

Business Report, 8 Sep 2022

Price reaction to curatorship (1 Aug 2022)

Fell about 52% intraday to about R0.17; about 73% down over the prior three years

The Star, 2 Aug 2022

Alternative report

Fell from 35c to 18c on the curatorship news

TradingView summary

Historical reference

R2.98 per share (September 2016; about 539m shares)

Value Investors Club, 27 Sep 2016

Market capitalisation (ZAR Mn)

FY2021

FY2022

Market cap

413.0289.1

Capital Markets

ItemDisclosure

P/E, EV/EBITDA, EV/Sales

Not meaningful (loss-making; no current price)

P/B

Not meaningful (negative equity at 31 Dec 2021)

Analyst consensus

None identified

Dividends

Nil in FY2021 and FY2022 (ShareData).

Buyback authority

General authority sought at the 1 Oct 2024 AGM (special resolution 1). Directors stated no specific intention to repurchase. Inoperable once delisted under JSE rules

Treasury shares

76.168m (Interim H1 FY2022)

Credit ratings

GCR (22 May 2017): BBB(ZA) long-term and A3(ZA) short-term national scale, outlook Stable; international scale B+, outlook Negative. Current status not disclosed; presumably lapsed. No Moody's, S&P or Fitch ratings

Analyst Conclusions

Management guidance

The only guidance is qualitative. Management intends to realise assets, reduce operating costs (by about 80% if the disposals complete), resolve disputes with the CICL liquidators and enforce the Trustco award. IAR22 warns that a favourable outcome in the short to medium term is not guaranteed. No consensus forecasts exist.

Bull case

  1. Recoveries could be large relative to the share price. If the R50m-plus-interest Trustco award is collected, the gross amount could be more than 1.6 times the last market capitalisation of R30.6m. The award has been running interest since December 2020.

  2. The legal position has held up so far. Conduit defeated the 2024 winding-up applications with costs, won the arbitration, and won at the Financial Services Tribunal (November 2024).

Bear case

  1. No audited information since FY2022. Results work has been halted indefinitely. Shareholders cannot value the company, and the delisting removes JSE oversight and price discovery.

  2. The regulator is blocking exits. The Prudential Authority has refused CLL's buyer twice. CLL's run-off costs keep consuming scarce cash, and the company admits it lacks surplus capital.

  3. Litigation could grow. Beyond the current R37.4m claim, the CICL liquidation involves allegedly missing funds (about R156–160m reported) and large policyholder claims (R580m reported). Further claims against Conduit or former management cannot be ruled out. Board depletion in September 2025 weakens the company's capacity to respond.

Catalysts and monitorables (next 12 months)

MonitorableWhy it matters
Judgment or settlement in the R37.4m CICL liquidators' claimIt is the stated gate for resuming results work
Collection or settlement of the Trustco Properties awardThe largest potential cash inflow
Prudential Authority approval of a Section 50 transfer of CLLRemoves run-off costs and capital burden
Appointment of new independent directors and an Audit & Risk chairBasic governance
Publication of H1 FY2023 and FY2023 resultsRestores information to shareholders
Final winding-up of CICL and any liquidation dividend or claimsDetermines the final contingent exposure
Any shareholder communication from the unlisted companyCommunication channel uncertain after delisting

Analyst verdict

Conduit Capital is no longer an investable operating company in any conventional sense. It is a residual legal and administrative vehicle left behind by a failed insurance group. The strategy pursued from 2015 to 2022 combined a rapidly growing, thinly capitalised niche insurer with a concentrated value-investing equity portfolio. That combination left almost no margin for error. Constantia doubled its premium base on the back of solvency relief reinsurance, not equity capital. Underwriting losses peaked at about R259 million in FY2019. By December 2021, CICL's solvency cover was negative and consolidated equity had turned negative. Two attempts at recapitalisation failed: the Trustco/LSH structure in 2020 and the R500 million Mmuso deal in 2022. The Prudential Authority's intervention in July 2022 followed. Management's underwriting turnaround was real, but it came too late, and the regulator was evidently unconvinced by it.

What remains has binary value. On one side are contingent assets: a R50 million-plus-interest arbitration award against a Namibian counterparty, a solvent but sub-scale run-off life insurer, and minority stakes of uncertain value. On the other side are contingent liabilities arising from the CICL liquidation, a regulator that has twice blocked an exit, and a board reduced to four members after September 2025. The decision to suspend all financial reporting until the liquidators' claim is resolved means shareholders cannot assess solvency or net asset value. The JSE removed the listing because Conduit failed to remedy its non-compliances, and the company did not appeal. That suggests the board itself saw little realistic prospect of restoring compliance.

For anyone still holding shares, the investment case rests on the legal recoveries exceeding the claims plus the cost of running off and transferring CLL. On the public record, the likely outcome cannot be assessed with confidence. On the evidence available, the position should be treated as a speculative, illiquid litigation claim of uncertain value. It is not a going-concern equity. For competitive intelligence purposes, Conduit and Constantia are now relevant mainly as a case study in South African prudential enforcement, not as a market participant.


Data gaps and discrepancies

ItemIssue
FY2023 to FY2025 financialsNot published; work halted 30 Sep 2025
FY2022 balance sheet and cash flow detailIn IAR22 pages 40–128; not extractable in this research pass
Share countAGM notice (105.1m listed) conflicts with the interim report (764.4m issued; 688.3m outstanding)
Date of loss of control of CICL"End of July 2022" (IAR22; SENS 28 Jun 2024) vs "end of July 2023" (SENS 30 Sep 2024; 30 Jun 2025). 2022 is consistent with the curatorship date
Riskowitz resignation date21 Jul 2022 (IAR22) vs May 2022 (Business Day)
Riskowitz shareholding4.47% (MarketScreener) is inconsistent with the company's share count
CLAH sale to AffinityCompletion not confirmed
Top shareholders and executive payIn IAR22 (page 127; note 42); not extracted
Competitor and market-size figuresdeliberately omitted

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedAge*EducationBackground

Melvyn Lubega

Independent non-executive Chairman (since 1 Oct 2023); chairs the Remuneration & Nomination Committee; member of Audit & Risk, Investment, and Social & Ethics Committees

15 March 2021

34

BBusSc (UCT); MSc and MPP (Oxford, Rhodes Scholar)

Actuary by training; entrepreneur and investor; board member of Adcorp Holdings (JSE: ADR) committees

Leo Chih Hao Chou

Chief Executive Officer (since 1 Oct 2023); previously non-executive director

9 October 2017

43

BCom (UNISA)

Long-serving board member through the Riskowitz era; Investment and Remuneration Committee member

Lourens Erasmus Louw

Financial Director (reappointed 1 Jan 2023)

Joined June 2003; FD from October 2004

53

BCom (Stellenbosch); member of the SA Institute of Stockbrokers

Former FD and compliance officer of Irish & Menell Rosenberg (Appleton Group); Constantia Group CFO from February 2021

Geoffrey Edgar Bolton Hacking

Independent non-executive director; Lead Independent Director (since 29 Sep 2023); chairs Social & Ethics; member of Audit & Risk (from 30 Aug 2024)

3 April 2023

65

MBChB (UCT); FF Rad (D) (SA); FRCR (London)

Radiologist and former director of Morton & Partners Radiologists; value investor with more than 45 years' experience

Board of Directors — Sean Michael Riskowitz

NameRoleTenureNotes

Sean Michael Riskowitz

CEO and executive director

31 Jul 2015 – 21 Jul 2022

BCom (Wits); founder of Riskowitz Capital Management and Protea Asset Management. Discrepancy: IAR22 gives a resignation date of 21 July 2022; Business Day (29 Jan 2024) reported May 2022

Peter Goeffrey Todd

CEO (21 Jul 2022 – 1 Oct 2023); then executive director until 19 Sep 2025

2022 – 2025

BCom LLB (UCT); former Chief Executive of Mutual & Federal; past President of the Insurance Institute of SA; co-founder of Repair Solutions; Constantia CEO from 2020

Christian Richard Solberg

Independent non-executive director; Audit & Risk Committee chair; Investment Committee chair

3 Apr 2023 – 19 Sep 2025

Co-founder of Sun Mountain Partners (Boston); BA (Middlebury), MBA (MIT)

Ronald Stuart Napier

Independent non-executive Chairman

31 Mar 2015 – 17 Nov 2022

MA (Oxon)

Nonzukiso Siyotula

Lead Independent Director; Audit & Risk chair

24 Mar 2020 – 9 Dec 2022

CA(SA), ACMA, MBA

Adrian John Maizey

Non-executive director; Investment Committee chair

20 Feb 2017 – 18 Jul 2022

CFO and President of Protea Asset Management; MBA (Harvard), CPA (USA)

Bianca Yan

Financial Director

5 Feb 2021 – 31 Dec 2022

CA(SA) (Wits)

Directors' Remuneration

CommitteeMembers (FY2022)Meetings attended

Audit & Risk

N Siyotula (Chair), RS Napier, M Lubega

3 each

Social & Ethics

N Siyotula (Chair), M Lubega, SM Riskowitz

2 each

Nomination

RS Napier (Chair), M Lubega, N Siyotula

0

Remuneration

M Lubega (Chair), RS Napier, N Siyotula, LCH Chou

1 each

Investment

AJ Maizey (Chair), M Lubega, SM Riskowitz, LCH Chou

3 each

Directors' Remuneration — Non-executive director fees, FY2024

ItemDisclosure

Non-executive director fees, FY2024

Flat R10,000 per non-executive director (Chairman, committee chairs and members alike), excluding VAT (IAR22, AGM special resolution 3)

Executive incentive structure (policy)

STI plus LTI (50% cash and 50% equity, three-year rolling). Combined incentive cap for non-CEO executives: 0–90% of basic salary. CEO cap: 0–202.5% of basic salary

Proposed changes ("in principle")

Option to take salary in shares; NAV high-water mark; five-year LTI period; malus and clawback; "Accelerated Buy-in" LTI structure

Individual executive pay (salary, bonus, total)

Disclosed in note 42 of IAR22 (page 94).

Service contracts

Six-month notice period; restraint of trade of up to two years; some contracts carry minimum employment periods of two to four years

Major Shareholders

HolderStakeSource / note

Treasury shares (held by group)

76.168m shares (about 10.0% of 764.444m issued)

Interim H1 FY2022

Sean Riskowitz (former CEO)

23,073,592 shares (4.47%, as stated by aggregator)

MarketScreener, data dated Aug 2025. Discrepancy: 4.47% implies about 516m shares outstanding, against 688.3m outstanding per company disclosure

Major shareholders list

Published on IAR22 page 127

—

Directors' interests

Published in IAR22 note 50 (pages 121–122)

—

Competitive Landscape

Competitors by Segment

Constantia segmentCompetitors (illustrative)Positioning of Constantia

Health (gap cover, primary health)

Other gap cover and health insurance product carriers and UMAs in South Africa

Largest Constantia line (about R1.1bn annualised gross premium); combined ratio about 92%

Medical malpractice

Medical Protection Society (a discretionary mutual) and other indemnity providers

EthiQal was a disruptive insured alternative; gross premium about R237m annualised

P&C Specialty (guarantee, liability)

Lombard Insurance, Bryte, Santam Specialist, Guardrisk (cell captive)

Niche, mid-size

P&C General (motor, property)

Santam, OUTsurance, Old Mutual Insure, Hollard, Discovery Insure

Sub-scale; loss-making (combined ratio 140.5%)

Funeral and life

Hollard, Old Mutual, Sanlam, Assupol, AVBOB

Sub-scale; exited funeral parlours 2020

Listed investment holding companies (value style)

Other small JSE investment holding companies

Discount to NAV; concentrated portfolio

Benchmark (FY2022 or latest)

Revenue (R m)

Revenue growth (%)

Conduit Capital

1,138.01.4

Recent Developments

Very few public disclosures have been made since the December 2025 delisting, so this register covers the full suspension period from 2024 onward. As an unlisted company, it no longer has to publish on SENS.

Company Snapshot

8

Employees

1993

Founded

SWOT Analysis

Strengths

  • Holding company survived the liquidation attempt. The Western Cape High Court dismissed, with costs, the applications to wind up Conduit and Conduit Ventures (2 Aug 2024).
  • A large arbitration award. AFSA awarded CRIH R50 million plus interest from 10 December 2020 against Trustco Properties (14 Jun 2024). Seven-plus years of interest could add materially to this.
  • Very low overhead. The head office has five remote employees and no office premises (IAR22). Non-executive fees are R10,000 per director for FY2024.
  • Underwriting turnaround was proven before the liquidation. FY2022 combined ratio was below 100%, with the first net underwriting profit since 2016 (trading statement, 13 Jun 2024). Health combined ratio was 92.1% and Medical Malpractice 85.6% in H1 FY2022.
  • Company-level FY2022 statements were not modified. Only the group statements were disclaimed (IAR22).
  • CLL was solvent. Its provisional SCR cover was 2.28 at 31 Dec 2021 (Interim H1 FY2022), which supports a Section 50 transfer.

Weaknesses

  • The core asset has gone. CICL made up about 94.4% of group revenue (H1 FY2022) and is in liquidation.
  • Negative equity. Equity attributable to the parent was −R58.5 million at 31 Dec 2021.
  • Disclaimed audit and missing results. FY2022 group statements were disclaimed. No results exist for FY2023 to FY2025, and work on them was halted on 30 Sep 2025.
  • Board depletion. The Audit & Risk chair and an executive director resigned on 19 Sep 2025, and no replacements were disclosed.
  • Persistent investment losses. The investment result was −R33.3m in H1 FY2021 and −R46.4m in H1 FY2022, which offset insurance gains.
  • Inconsistent disclosures. The share count in the AGM notice (105.1m) conflicts with the interim report (688.3m outstanding). SENS announcements give the loss of control of CICL as July 2022 in some places and July 2023 in others.

Opportunities

  • Recovering the Trustco award (R50m plus interest), which would be a large amount relative to the last market capitalisation of R30.6m.
  • A Section 50 transfer of CLL to a licensed insurer, which would release capital and remove regulatory costs (SENS 30 Sep 2025).
  • Monetising residual stakes: Century 21 SA (51%; 62.6% annualised return on capital in H1 FY2022), Oraclemed (30%), ASOC Fund I, and Conduit Ventures holdings.
  • Defeating the R37.4m CICL claim, which the board considers immaterial (SENS 3 Sep 2025).
  • Possible recoveries in the CICL liquidation if creditors are fully paid. This is speculative.
  • Selling the CLL licence. It was valued at about R55m in the lapsed TMM deal (including CRIH), which shows there is buyer interest, subject to regulatory approval.

Threats

  • Litigation by the CICL liquidators. Beyond the R37.4m claim, Business Day reported that the late liquidator Cloete Murray sought a section 417 inquiry into about R156–160m of allegedly missing money, R580m of policyholder claims and R228m of debtors (29 Jan 2024).
  • The Prudential Authority has twice rejected the CLL buyer (June 2024 and March 2025), which shows how hard a regulator-approved exit will be.
  • Trustco's ability to pay the award, and the difficulty of cross-border enforcement (Trustco Properties is Namibian).
  • Shareholders hold unlisted shares with no exchange liquidity since 19 Dec 2025.
  • Cash burn while CLL is in run-off, given that the company says it lacks surplus capital (SENS 30 Sep 2025).
  • Reputational and contagion risk. CRIH's own risk register lists "reputational and contagion risk" as a top risk (IAR22).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
4 Apr 2024SENS: CICL liquidators applied on 2 April 2024 to wind up Conduit and Conduit VenturesExistential threat to the holding company
24 Apr 2024Addendum #10 to the TMM agreement; deadline extended to 31 May 2024 at the regulator's requestDeal timeline slipping
28 May 2024Addendum #11 (deadline 30 Jun 2024). JSE refuses a further extension for the circular because FY2022 and FY2023 results are outstandingJSE compliance pressure
3 / 7 Jun 2024Prudential Authority declines TMM's applicationMain exit route blocked
13 Jun 2024FY2022 trading statement: LPS 44.19c–48.41c; first net underwriting profit since 2016; R225.0m impairmentsFirst FY2022 numbers, 23 months after year end
14 Jun 2024AFSA tribunal orders Trustco Properties to pay CRIH R50m plus interest from 10 Dec 2020; counterclaim dismissedLargest identifiable recovery asset
25 Jun 2024Addendum #12: deadline extended to 31 Jan 2025; TMM to fund CLL operating costs from 1 Jul 2024, deducted from the priceCost relief for Conduit
28 Jun 2024Quarterly progress report; FY2022 AFS to be issued on a disclaimed basisAudit quality red flag
2 Aug 2024Winding-up applications dismissed with costsHolding company survives
21 Aug 2024IAR22 approved; Hacking joins the Audit & Risk Committee (effective 30 Aug)Governance alignment with King IV
30 Aug 2024FY2022 AFS and IAR published (disclaimed group opinion)Results gap partly closed
30 Sep 2024Quarterly report; FST hearing set for 20 Nov 2024—
1 Oct 2024Virtual AGMVotes on director elections, auditor reappointment and R10,000 flat NED fees
18 Oct 2024Renewal of cautionaryRoutine
20 Nov 2024Financial Services Tribunal overturns the Prudential Authority's decision and refers it back for reconsiderationRevives the TMM sale
12 Dec 2024Quarterly report; FST order filed in the High Court (Pretoria) as a civil judgmentLegal standing strengthened
26 Feb 2025Prudential Authority reconsideration meeting—
7 Mar 2025Prudential Authority confirms its refusalTMM sale blocked again
11 Mar 2025Addendum #14: deadline extended to 16 May 2025Last attempt
28 Mar 2025Quarterly progress report—
20 May 2025TMM will not challenge; agreement lapsesNo exit for CLL
30 Jun 2025Quarterly report; H1 FY2023 interim results submitted to auditors for a high-level review; FY2023 audit ongoingReporting appeared to be progressing
3 Sep 2025CICL liquidators sue Conduit for R37.4m in the Western Cape High Court over alleged advancesNew contingent liability
19 Sep 2025Solberg (Audit & Risk chair) and Todd (executive director) resignBoard weakened
30 Sep 2025Quarterly report; all work on H1 FY2023 and FY2023 results halted until the litigation concludes; Section 50 transfer of CLL consideredRemoves any prospect of the suspension being lifted
19 Nov 2025Renewal of cautionaryLast cautionary
11 Dec 2025JSE announces removal of the listing for failure to remedy non-compliances; Conduit did not appealEnd of the public listing
12 Dec 2025Last day to trade (off-market)—
18 Dec 2025Record date—
19 Dec 2025Listing removedShareholders now hold unlisted shares

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Revenue by Segment (FY2019–FY2021): P&C Specialty rose from ZAR 202 Mn in FY2019 to ZAR 337 Mn in FY2021.
Conduit Capital Limited — Revenue by Segment (FY2019–FY2021)
Series (ZAR Mn)FY2019FY2020FY2021
P&C Specialty202293337
P&C General483277221
EthiQal (Medical Malpractice)156204215

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. ShareData Online — Conduit Capital company page and latest results (FY2022 vs FY2021 per-share data, market cap, rename note) (sharedata.co.za)
  2. ShareData Online — Conduit summary fact sheet (sharedata.co.za)
  3. ShareData Online — Latest news (cautionary 19 Nov 2025; removal of listing 11 Dec 2025) (sharedata.co.za)
  4. JSE GEN — Removal of Listing Announcement, 11 Dec 2025 (sharedata.co.za)
  5. Conduit Capital Integrated Annual Report 2022 (approved 21 Aug 2024) (senspdf.jse.co.za)
  6. Conduit Capital website (conduitcapital.co.za)
  7. SENS — Quarterly Progress Report, 28 Jun 2024 (senspdf.jse.co.za)
  8. SENS — Quarterly Progress Report, 30 Sep 2024 (sharedata.co.za)
  9. SENS — Quarterly Progress Report, 12 Dec 2024 (sharedata.co.za)
  10. SENS — Quarterly Progress Report, 28 Mar 2025 (sharedata.co.za)
  11. SENS — Quarterly Progress Report, 30 Jun 2025 (sharedata.co.za)
  12. SENS — Quarterly Progress Report, 30 Sep 2025 (sharedata.co.za)
  13. SENS — Voluntary Announcement, Claim by CICL Liquidators, 3 Sep 2025 (sharedata.co.za)
  14. SENS — Liquidation Application Update, 2 Aug 2024 (sharedata.co.za)
  15. SENS — Changes to the Board Committee, 21 Aug 2024 (sharedata.co.za)
  16. SENS — Trading Statement FY2022, 13 Jun 2024 (senspdf.jse.co.za)
  17. SENS — Renewal of Cautionary, 11 Jun 2024 (senspdf.jse.co.za)
  18. SENS — Renewal of Cautionary, 18 Oct 2024 (senspdf.jse.co.za)
  19. Interim results, six months ended 31 Dec 2021 (senspdf.jse.co.za)
  20. Interim results, six months ended 31 Dec 2020 (senspdf.jse.co.za)
  21. FY2021 results document (senspdf.jse.co.za)
  22. FY2020 reviewed provisional results: and: senspdf.jse.co.za · senspdf.jse.co.za
  23. FY2020 interim results (senspdf.jse.co.za)
  24. FY2019 reviewed results (senspdf.jse.co.za)
  25. FY2017 audited results (SENS, 27 Sep 2017) (sharedata.co.za)
  26. FY2017 trading statement (12 Sep 2017) (sharedata.co.za)
  27. Further trading statement H1 FY2018 (20 Feb 2018) (sharedata.co.za)
  28. FY2016 audited results (30 Sep 2016) (sharedata.co.za)
  29. GCR credit rating announcement (22 May 2017) (sharedata.co.za)
  30. Board change SENS (1 Jun 2016) (sharedata.co.za)
  31. Board change SENS (21 Feb 2017) (sharedata.co.za)
  32. Board change SENS (10 Oct 2017) (sharedata.co.za)
  33. Trustco SENS — Herboths transaction (11 Feb 2020) (senspdf.jse.co.za)
  34. Ecofin Agency — Conduit sells Constantia and Conduit Ventures to LSH (11 Dec 2019) (ecofinagency.com)
  35. Business Day — Conduit Capital agrees to R500m investment (20 Dec 2021) (businesslive.co.za)
  36. Business Day — Conduit Capital and Mmuso R500m deal collapses (21 Jun 2022) (businessday.co.za)
  37. Business Day — Inside Constantia liquidator Cloete Murray's last days (29 Jan 2024) (businessday.co.za)
  38. Business Report — Conduit Capital won't oppose liquidation of Constantia Insurance (8 Sep 2022) (busrep.co.za)
  39. Moonstone — Conduit Capital selling life and health insurance business (moonstone.co.za)
  40. News24 — Client database of liquidated group Constantia sold for R20m (28 Dec 2022) (news24.com)
  41. The Star — Placing Constantia under curatorship "premature" (2 Aug 2022) (ziniounlimited.com)
  42. Ghostmail (Ghost Mail M&A weekly) — Conduit/TMM transaction (ghostmail.co.za)
  43. FilingReader — Board resignations (19 Sep 2025) (filingreader.com)
  44. FilingReader — R37.4m claim (3 Sep 2025) (filingreader.com)
  45. MarketScreener — Sean Riskowitz insider profile (marketscreener.com)
  46. TradingView — CND company summaries: and: tr.tradingview.com · it.tradingview.com
  47. Value Investors Club — Conduit Capital write-up (27 Sep 2016) (valueinvestorsclub.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.